Cart
sales@molnova.com
BET bromodomain inhibitor
CAS No. 1505453-59-7
BET bromodomain inhibitor( MDK3597 | MDK-3597 | MDK 3597 | BET bromodomain inhibitor )
Catalog No. M12098 CAS No. 1505453-59-7
It is a BET bromodomain inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 50 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 267 | In Stock |
|
| 50MG | 462 | In Stock |
|
| 100MG | 672 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBET bromodomain inhibitor
-
NoteResearch use only, not for human use.
-
Brief DescriptionIt is a BET bromodomain inhibitor.
-
DescriptionIt is a BET bromodomain inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsMDK3597 | MDK-3597 | MDK 3597 | BET bromodomain inhibitor
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorBET bromodomain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1505453-59-7
-
Formula Weight400.26
-
Molecular FormulaC20H15Cl2N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(N)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=CC(Cl)=CC=C3C4=C1ON=C4C
-
Chemical Name(S)-2-[8-Chloro-6-(4-chloro-phenyl)-1-methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Xiao Y, et al. Rheumatology (Oxford). 2015 Aug 3
molnova catalog
related products
-
PBRM1-BD2-IN-8
PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor with PBRM1-BD2 Kd of 4.4 μM, PBRM1-BD2 IC50 of 0.16 μM, and PBRM1-BD5 Kd of 25 μM; PBRM1-BD2-IN-8 shows anti-cancer activity.
-
PBRM1-BD2-IN-5
PBRM1-BD2-IN-5 is a potent inhibitor of the PBRM1 Bromodomain, with dissociation constant (Kd) values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5 respectively, and an inhibitory concentration 50 (IC50) value of 0.26 μM for PBRM1-BD2.
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
